Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study.

Autor: Gold DT; Departments of Psychiatry & Behavioral Sciences and Sociology, Duke University Medical Center, Durham, NC, USA., Beckett T; Department of Orthopaedics, Orthopaedic Associates of Grand Rapids Research and Education Institute, Grand Rapids, MI, USA., Deal C; Department of Rheumatology, Center for Osteoporosis and Metabolic Bone Disease, The Cleveland Clinic Foundation, Cleveland, OH, USA., James AL; Proactive Orthopaedics at Columbia Orthopaedic Group LLP, Adult Health CNS, Columbia, MO, USA., Mohseni M; Department of Medicine, Division of Bone and Mineral Diseases, Washington University School of Medicine, St Louis, MO, USA., McMillan A; Observational Research Adelphi Real World, Bollington, Macclesfield, UK., Bailey T; Observational Research Adelphi Real World, Bollington, Macclesfield, UK., Pearman L; Global Medical Affairs, Radius Health, Inc, Boston, MA, USA., Caminis J; Global Medical Affairs, Radius Health, Inc, Boston, MA, USA., Wang Y; Biostatistics, Radius Health, Inc, Boston, MA, USA. yawang@radiuspharm.com., Williams SA; Cobbs Creek Healthcare, Newtown Square, PA, USA., Kernaghan JM; Osteoporosis Center of Delaware County, Prospect Health Access Network, Springfield, PA, USA.
Jazyk: angličtina
Zdroj: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2024 Aug; Vol. 35 (8), pp. 1407-1415. Date of Electronic Publication: 2024 Apr 24.
DOI: 10.1007/s00198-024-07070-z
Abstrakt: Review of medical records from 173 women with osteoporosis who received abaloparatide treatment revealed that 96.0% had at least one visit for osteoporosis management and 55.5% had medication support group access. The most common reasons for discontinuing treatment were financial (31.2%) and tolerability (22.8%). Most patients (64.8%) completed treatment as prescribed.
Purpose: Abaloparatide is approved for the treatment of women with postmenopausal osteoporosis at high risk for fracture. This study evaluated real-world treatment patterns for patients new to abaloparatide, regardless of osteoporosis treatment history.
Methods: Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.
Results: A total of 173 patients were enrolled (mean [SD] age, 69.8 [7.4] years). At the time of abaloparatide treatment initiation, 78.6% had received other osteoporosis medications. Mean (SD) time from discontinuation of osteoporosis medications prior to initiation of abaloparatide was 1.7 (3.2) years. Twenty-four months of follow-up data from the initiation date of abaloparatide was collected from 94.0% of patients and 6.0% of patients had 12-24 months of follow-up. During the follow-up period, 96.0% of patients had at least one visit for osteoporosis management and 55.5% had access to a medication support program. The median duration of therapy was 18.6 months and 105/162 (64.8%) completed abaloparatide treatment as prescribed. The most common reasons for treatment discontinuation were financial (31.2%) and tolerability (22.8%). Following completion of a course of treatment with abaloparatide, 82/162 (50.6%) patients transitioned to another osteoporosis medication. The median time between abaloparatide treatment course completion and the initiation of follow-on medication was 21 days.
Conclusion: Most patients completed treatment with abaloparatide as prescribed, and over half continued with an antiresorptive agent. This favorable conduct may be the result of regular follow-up visits and accessibility to both medication and patient support services.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: